- Capricor sues Nippon Shinyaku over Duchenne drug 'pricing flaw' and launch prepCapricor Therapeutics said Thursday it has filed a lawsuit against Nippon Shinyaku over a distribution and commercialization agreement for deramiocel, a cell therapy candidate for Duchenne muscular…Endpoints · 2mo ago↗ source
- Odyssey raises more than $300M as biotech goes publicOdyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night. Odyssey began trading on the Nasdaq on Friday. The b…Endpoints · 2mo ago↗ source
- Astellas touts data from early test of stem cell-derived eye therapyAstellas reported promising results with its stem cell-derived therapy in an age-related eye disease, though data in a handful of high-dose patients in the early-stage study raised questions. The…